HIGH LEVEL PRODUCTION OF SARS-COV-2 ANTIBODIES ALSO AFFECTED THE
FORMATION OF ANTI-NUCLEAR AUTOANTIBODIES
Abstract
Background: In SARS-CoV-2 infection, in addition to the
production of virus-specific antibodies, autoantibodies can also be
produced, which attack self-structures and worsen the prognosis. We
hypothesized that overproduction of virus-specific antibodies may also
trigger autoantibody production. Methods: To test this
hypothesis, the antinuclear antibody (ANA) positivity rate was examined
in samples with high and low (i.e., negative) anti-SARS-CoV-2 antibody
levels. A quantitative ELISA test kit with a dynamic measurement range
of 1-475 RU/mL was used to determine Sars-CoV-2 antibodies. In the high
SARS-CoV-2 antibody criterion, it was required to have the last quarter
antibody level (>235 RU/mL) in the ELISA calibration curve.
For low antibody levels, the requirement was <15 RU/mL.
Anti-SARS-CoV-2 antibody levels of 1222 samples were examined and 62 (33
men, 29 women) samples were determined to have high antibodies (high
group; HG). Among the samples with low antibody levels, 62
gender-matched samples were selected by randomization (low group; LG).
ANA positivity was analyzed with 3 different commercial ELISA test kits
(anti-dsDNA, anti-ENA, anti-Hep-2 nucleus; Y immunoTEK, Turkey). Total
IgG levels were also measured to evaluate the difference in total
antibody levels. Results: Anti-SARS-CoV-2 antibody levels were
413 ± 72 RU/mL and 3.8 ± 1.4 RU/mL for HG and LG, respectively
(p<0.001). The ANA positivity rate was found to be significantly
higher in HG than in LG (anti-dsDNA 9/62, 14.5% - 19/62, 30.7%; anti-
ENA 10/62, 16.1% - 22/62, 35.5%; anti- Hep-2 nükleus 8/62, 12.9% -
20/62, 32.3% respectively). There was no difference between total IgG
levels (HG; 11.1 ± 3.0 and LG; 10.6 ± 3.4 mg/mL) (p>0.05).
Conclusions: As a result, it was determined that high levels of
SARS-CoV-2 antibody production were associated with the formation of
ANA. This suggests that SARS-CoV-2 antibody and ANA production have
similar mechanisms or pathways.